Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment

Pre-treatment screening of individuals for human leukocyte antigens (HLA) HLA-B*57:01 is recommended for the prevention of life-threatening hypersensitivity reactions to abacavir, a drug widely prescribed for HIV treatment. However, the implementation of screening in clinical practice is hindered by the slow turnaround time and high cost of conventional HLA genotyping methods. We have developed a biosensor platform using interdigitated electrode (IDE) functionalized with a monoclonal antibody to detect cells expressing HLA-B*57:01. This platform was evaluated using cell lines and peripheral blood mononuclear cells expressing different HLA-B alleles. The functionalized IDE sensor was able to specifically capture HLA-B*57:01 cells, resulting in a significant change in the impedance magnitude in 20 min. This IDE platform has the potential to be further developed to enable point-of-care HLA-B*57:01 screening.

[1]  Efstratios Skafidas,et al.  A Label-Free, Quantitative Fecal Hemoglobin Detection Platform for Colorectal Cancer Screening , 2017, Biosensors.

[2]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[4]  Sundhiya Mandalia,et al.  Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience , 2007, AIDS.

[5]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update , 2016, Clinical pharmacology and therapeutics.

[6]  Lei Wang,et al.  A sensitive DNA capacitive biosensor using interdigitated electrodes , 2016, Biosensors and Bioelectronics.

[7]  David Nolan,et al.  Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? , 2003, Journal of HIV therapy.

[8]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[9]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[10]  James Robinson,et al.  The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..

[11]  S. Caillat-Zucman,et al.  Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. , 2007, Journal of acquired immune deficiency syndromes.

[12]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[13]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[14]  C. Thorn,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen‐B Genotype and Allopurinol Dosing , 2013, Clinical pharmacology and therapeutics.

[15]  C. E. Bennett,et al.  B and T lymphocytes: methodology and normal ranges. , 1977, Annals of clinical and laboratory science.

[16]  E. Alocilja,et al.  A high density microelectrode array biosensor for detection of E. coli O157:H7. , 2005, Biosensors & bioelectronics.

[17]  J Rossjohn,et al.  Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. , 2011, Tissue antigens.

[18]  B. Tank,et al.  Cutaneous drug reactions. , 1996, Indian journal of dermatology, venereology and leprology.

[19]  Efstratios Skafidas,et al.  An interdigitated electrode biosensor platform for rapid HLA-B*15:02 genotyping for prevention of drug hypersensitivity. , 2018, Biosensors & bioelectronics.

[20]  Heidemarie Neitzel,et al.  A routine method for the establishment of permanent growing lymphoblastoid cell lines , 1986, Human Genetics.

[21]  J. McCluskey,et al.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.

[22]  I. James,et al.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Efstratios Skafidas,et al.  GFAP Antibody Detection Using Interdigital Coplanar Waveguide Immunosensor , 2016, IEEE Sensors Journal.

[24]  Efstratios Skafidas,et al.  Lab on a chip sensor for rapid detection and antibiotic resistance determination of Staphylococcus aureus. , 2016, The Analyst.

[25]  O. Naderer,et al.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.

[26]  G. Novelli,et al.  Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01 , 2014, The Pharmacogenomics Journal.

[27]  C. Sukasem,et al.  HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity , 2015, Front. Genet..

[28]  S. Mallal,et al.  HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. , 2007, Tissue antigens.

[29]  Luke P. Lee,et al.  Sample concentration and impedance detection on a microfluidic polymer chip , 2008, Biomedical microdevices.

[30]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[31]  David Nolan,et al.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. , 2008, Immunity.